C. Frost

发表

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

C. Frost, Jessie Wang, S. Nepal, 2012, British journal of clinical pharmacology.

Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.

A. Shenker, C. Frost, Jessie Wang, 2014, British journal of clinical pharmacology.

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation

K. Kowalski, B. Cirincione, C. Frost, 2018, CPT: pharmacometrics & systems pharmacology.

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism

C. Frost, R. Boyd, R. Boyd, 2017, CPT: pharmacometrics & systems pharmacology.

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

C. Frost, Jessie Wang, Y. Barrett, 2012, Thrombosis and Haemostasis.

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

C. Frost, Jessie Wang, Y. Barrett, 2013, British journal of clinical pharmacology.

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

A. Shenker, C. Frost, Jessie Wang, 2013, British journal of clinical pharmacology.

Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats

A. D. Rodrigues, W. Humphreys, K. He, 2013, Drug Metabolism and Disposition.

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban

A. Shenker, C. Frost, Jessie Wang, 2015, Clinical Pharmacokinetics.

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects

A. Shenker, C. Frost, Jessie Wang, 2018, Clinical pharmacology : advances and applications.

Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study

Z. Wang, C. Frost, Jessie Wang, 2017, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis

C. Frost, Jessie Wang, R. Boyd, 2016, Journal of clinical pharmacology.

Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model

T. Wakefield, R. Knabb, D. Coleman, 2017, Arteriosclerosis, thrombosis, and vascular biology.

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

C. Frost, Jessie Wang, F. LaCreta, 2013, Clinical pharmacology : advances and applications.

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects

C. Frost, Jessie Wang, A. Schuster, 2017, Clinical pharmacology : advances and applications.

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

A. Shenker, C. Frost, Y. Barrett, 2010, Thrombosis and Haemostasis.

DMD050575 906..915

A. D. Rodrigues, W. Humphreys, K. He, 2013 .

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

C. Frost, V. Ly, S. Garonzik, 2021, Drugs in R&D.

Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery

C. Frost, F. LaCreta, T. Leil, 2014, CPT: pharmacometrics & systems pharmacology.

New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans

M. Bouvier, Lester Hui, C. Frost, 2022, Platelets.

Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects.

S. Badawy, C. Frost, Jessie Wang, 2015, Clinical therapeutics.

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects

C. Russo, D. Seiffert, R. Knabb, 2018, British journal of clinical pharmacology.

Apixaban Single‐Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration

A. Shenker, C. Frost, Y. Barrett, 2021, Clinical pharmacology in drug development.

Randomized, blinded, placebo‐ and positive‐controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval

C. Frost, S. Nepal, R. Reeves, 2015, Journal of clinical pharmacology.

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects

C. Frost, Jessie Wang, A. Schuster, 2013, Clinical pharmacology : advances and applications.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.

C. Frost, Jessie Wang, F. LaCreta, 2014, International journal of clinical pharmacology and therapeutics.

Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults.

C. Frost, F. LaCreta, R. Frost, 2016, Clinical therapeutics.

Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma

C. Frost, Jessie Wang, Y. Barrett, 2017, Thrombosis and Haemostasis.

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

C. Frost, Jessie Wang, Y. Barrett, 2014, Clinical pharmacology : advances and applications.

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Wonkyung Byon, Charles E. Frost, C. Frost, 2019, Clinical Pharmacokinetics.

Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

A. Shenker, C. Frost, Jessie Wang, 2016, American Journal of Cardiovascular Drugs.

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects

Giridhar Tirucherai, Charles Frost, C. Frost, 2013, American Journal of Cardiovascular Drugs.

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

W. Humphreys, K. He, C. Frost, 2009, Drug Metabolism and Disposition.

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

A. Shenker, C. Frost, Jessie Wang, 2015, British journal of clinical pharmacology.

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

R. Knabb, C. Frost, J. Lawrence, 2014, Annals of the New York Academy of Sciences.

Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban

W. Humphreys, K. He, C. Frost, 2013, Drug Metabolism and Disposition.

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

A. Shenker, C. Frost, Jessie Wang, 2016, Journal of clinical pharmacology.

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

R. Knabb, C. Frost, J. Lawrence, 2014, Annals of the New York Academy of Sciences.

Response to Letter to the Editor From Drs. Stöllberger and Finsterer

A. Shenker, C. Frost, Jessie Wang, 2016, Journal of clinical pharmacology.

Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects

A. Shenker, C. Frost, S. Nepal, 2018, Journal of clinical pharmacology.

apixaban Pharmacokinetics and Pharmacodynamics in Subjects With Renal Impairment : 1381212

A. Shenker, C. Frost, Jessie Wang, 2012 .

Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation

R. Knabb, C. Frost, J. Lawrence, 2014, Annals of the New York Academy of Sciences.

The contribution of apixaban renal clearance to total clearance

C. Frost, R. Boyd, 2015, Journal of Thrombosis and Thrombolysis.

Reversal of Apixaban Anticoagulation By 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

C. Frost, Jessie Wang, F. LaCreta, 2014 .

tolerability, Pharmacokinetics and Pharmacodynamics of Apixaban, Aspirin and Clopidogrel Following Coadministration in Healthy Subjects : 2-54-2000057

C. Frost, S. Nepal, F. LaCreta, 2014 .

lack of Pharmacokinetic Interaction Between Apixaban and Prasugrel in Healthy Subjects : 2-55-2000112

C. Frost, F. LaCreta, J. Pursley, 2014 .

"Center punch" and "whole spot" bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS.

Naiyu Zheng, Jianing Zeng, Yan Song, 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.

D. Seiffert, C. Frost, Zhaoqing Wang, 2023, Platelets.

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism

C. Frost, R. Boyd, W. Byon, 2017, CPT: pharmacometrics & systems pharmacology.

Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults.

C. Frost, F. LaCreta, R. Frost, 2016, Clinical therapeutics.

Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women

C. Frost, M. Shelton, G. Morse, 2002, Clinical drug investigation.

Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban

W. Humphreys, K. He, C. Frost, 2013, Drug Metabolism and Disposition.

Clinical Pharmacology: Advances and Applications The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects

C. Frost, Jessie Wang, A. Schuster, 2022 .

Advances and Applications

C. Frost, Jessie Wang, F. LaCreta, 2022 .